Legend Biotech (LEGN) Director Casey Patrick John Receives Award

What Happened

• Casey Patrick John, a director of Legend Biotech Corp (LEGN), received an award of 20,986 restricted share units (RSUs) on September 24, 2026. The RSUs were reported as acquired at $0.00 (no cash paid) and are a contingent right to receive ordinary shares upon settlement. This is an equity compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-24 (Form 4 filed 2026-09-28 — within the 2-business-day reporting window).
• Transaction type/code: Award/Grant (A).
• Amount: 20,986 RSUs acquired at $0.00 per RSU (total reported cost $0).
• Shares owned after transaction: Not specified as settled shares in the filing; these are contingent RSUs until vested/settled.
• Footnotes of note:
  • Each RSU represents a contingent right to receive one ordinary share on settlement.
  • Ordinary shares may be represented by American Depositary Shares (ADSs); each ADS = 2 ordinary shares.
  • Vesting: 1/3 of the RSUs vest on December 20, 2027; remaining RSUs vest in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.

Context

• This was a standard equity grant to a director as compensation; RSUs do not represent immediate transferable shares until they vest and are settled. Such awards are routine for directors and executives and should not be read as a direct buy/sell signal.